Sign in

CIK 0002007919 · <br>Emerging growth company

Inhibrx Biosciences, Inc.

Sign in to watch
Ticker
INBX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
990613523
Phone
(858) 795-4220
Business address
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA, CA, 92037
  1. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  2. 4 Open-market buy Chief Executive Officer bought 10,040 shares at an average $84.56 ($848,977)
  3. 4 Open-market buy Chief Executive Officer bought 10,000 shares at an average $99.88 ($998,784)
  4. 8-K Event Regulation FD disclosure
  5. 4 Open-market buy Director bought 5,000 shares at $100.00 ($500,000)
  6. 4/A Derivatives Options or other derivatives
  7. 4/A Derivatives Options or other derivatives
  8. 4/A Derivatives Options or other derivatives
  9. 4/A Derivatives Options or other derivatives
  10. 4 Open-market buy Director bought 5,000 shares at $100.00 ($500,000)
  11. 4 Open-market sale Director sold 1,500 shares at an average $109.03 ($163,543)
  12. 144 Insider Sale of Securities
  13. 144 Insider Sale of Securities
  14. 144 Insider Sale of Securities
  15. 4 Open-market sale Director sold 1,000 shares at an average $115.47 ($115,468)
  16. 144 Insider Sale of Securities
  17. 144 Insider Sale of Securities
  18. 4 Open-market buy Director bought 5,000 shares at $113.52 ($567,580)
  19. 4 Open-market buy Director bought 2,500 shares at $114.65 ($286,617)
  20. 4 Open-market buy Chief Executive Officer bought 25,000 shares at an average $105.82 ($2,645,399)

Page 1 of 8 · 158 filings